Aim: The present study aimed to determine the frequency and association of hypogonadism in men with type 2 diabetes mellitus. Material and Methods: This cross-sectional study was conducted on 242 type 2 DM male patients in the Department of General Medicine, Bahria International Hospital, Lahore from 16th January 2022 to 15th July 2022. The Androgen deficiency in aging male (ADAM) questionnaire was used for screening hypogonadal symptoms in the study group. The presence of low serum testosterone below 3 ng/mL and positive ADAM score was referred to as hypogonadism. T2DM patients with and without hypogonadism had their clinical and biochemical variables compared. Total testosterone, BMI, free testosterone, waist circumference, and sex hormone–binding globulin were measured. SPSS version 26 was used for data analysis. Results: Of the total 242 T2DM male patients, the prevalence of hypogonadism was 24.8% (n=60). The most prevalent symptoms in T2DM patients were hypogonadal symptoms. The overall mean age was 45.8± 9.63 years with range (25-70 years). Mean BMI value was 24.8 ± 3.64 kg/m2. The incidence of overweight and obese patients were 17.8% and 49.3% respectively. The prevalence of erectile dysfunction, reduced libido, and work performance deterioration in hypogonadism were 94.8%, 68.2%, and 56.3% respectively. T2DM patients without hypogonadism had lower a) incidence of diabetic neuropathy (18.6% vs. 43.8%; p=0.021), b) T2DM duration (5.3± 3.82 vs. 9.2± 4.9 years; P=0.002), c) occurrence of diabetic retinopathy (26.9% vs. 57.8%; P=0.006), and d) HbA1c (8.9± 1.53% vs. 9.9 ± 2.54%: P=0.005), and insulin therapy (21.5% vs. 45.8%: P=0.031) compared to those with hypogonadism. Conclusion: The present study found that prevalence of hypogonadism was 24.8% in type 2 diabetes mellitus. Patients with hypogonadism had higher HbA1c, higher prevalence of neuropathy and retinopathy, longer diabetic duration, and predominantly used insulin therapy than those T2DM patients without hypogonadism. Keywords: Hypogonadism, Type 2 diabetes mellitus, Androgen deficiency in aging male (ADAM).
Background and Aim: Hepatocellular carcinoma (HCC) is the primary liver cancer around the world, and it has now become the third leading cause of cancer-related mortality. With an increasing global incidence, HCC is becoming a major health burden. The incidence of HCC varies from 0.3% to 1.6% in Asian countries. The present study aimed to assess the clinical and etiological profile of hepatocellular carcinoma in a tertiary care hospital. Methodology: This retrospective study was conducted on 124 hepatocellular carcinoma patients in the Department of Gastroenterology, Jinnah Hospital, Lahore from June 2019 to May 2022. All the patients of age 10 years to 75 years fulfilling the diagnostic criteria were enrolled in this study. Patient’s cytohistological, clinical, radiological, and etiological data were recorded and analyzed. Individual relevant features were noted in pre-designed proforma. SPSS version 25 was used for data analysis. Results: Of the total 124 HCC patients, there were 78 (62.9%) male and 46 (37.1%) females. The overall mean age was 48.63±6.78 years. Liver cirrhosis was present in 91 (73.4%) patients out of which 14 (15.4%) were asymptomatic. The prevalent signs of hepatic decompensation were ascites 67 (54%) and Jaundice 23 (18.5%). Based on etiological data, the prevalence of the cryptogenic, Hepatitis B, and C were 58 (46.8%), 20 (16.1%), and 6 (4.8%) respectively. Tumor thrombosis was found in 18 (14.5%). Based on biopsy specimens, HCC with steatosis were seen in 19 (15.3%) patients. During surveillance, about 32 (25.8%) cirrhotic HCC patients were diagnosed. Conclusion: The present study found that the most prevalent etiology was hepatocellular carcinoma. Most patients were asymptomatic and had major complaints of abdominal pain with certain specific comorbidities. Hypertension, diabetes, and ischemic heart disease were the specific co-morbidities in hepatocellular carcinoma patients. In our population, the prevalent cause of HCC was Hepatitis B. Keywords: Clinical profile, Etiology, Hepatocellular Carcinoma
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.